In a case with billions of dollars at stake, McDermott Will & Emery partners William G. Gaede III and Sarah C. Columbia won a rare post-trial ruling for Amgen Inc. that booted a rival’s drug from the market.
The Jan. 5 order granted the attorneys’ motion for a permanent injunction blocking Sanofi and Regeneron Pharmaceuticals Inc. from selling Praluent, a biological drug used to treat high LDL cholesterol, for the next 12 years. Just days earlier, Gaede and Columbia had staved off the defendants’ bid to throw out a March 2016 verdict upholding the validity of two patents Amgen held for its own biologic Rapatha.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
